ABIOMED (ABMD) : 5 Wall Street analysts covering ABIOMED (ABMD) believe that the average level the stock could reach for the short term is $124.4. The maximum price target given is $145 and the minimum target for short term is around $101, hence the standard deviation is calculated at $18.88.
ABIOMED (ABMD) : 4 brokerage houses believe that ABIOMED (ABMD) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on ABIOMED (ABMD). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 7 Wall Street Analysts endorse the stock as a Buy with a rating of 1.71.
Also, Jefferies maintains their rating on the shares of ABIOMED (NASDAQ:ABMD). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $145 per share from $130 per share. The rating by the firm was issued on August 9, 2016.
ABIOMED (NASDAQ:ABMD): The stock opened at $117.98 on Thursday but the bulls could not build on the opening and the stock topped out at $118.57 for the day. The stock traded down to $117.05 during the day, due to lack of any buying support eventually closed down at $117.63 with a loss of -0.26% for the day. The stock had closed at $117.94 on the previous day. The total traded volume was 305,272 shares.
Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Companys products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD, a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000, a circulatory support system for the temporary support of acute heart failure patients in profound shock, and Symphony, a minimally invasive implantable cardiac assist device.